Olivia Goethals
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Olivia Goethals has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
Kurt Hertogs
Tibotec Virco Virology BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium
5 shared publicationsMarnix Van Loock
Janssen Infectious Diseases Discovery, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium
5 shared publicationsPeggy Geluykens
Discovery, Charles River Laboratories International Inc, Beerse, Belgium
4 shared publications- Ann Vos
Janssen Research and Development, LLC, Janssen Pharmaceutica NV, Antwerp, Belgium
3 shared publications - Dominique Schols
Molecular, Structural and Translational Virology Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Herestraat 49, Box 1049, 3000 Leuven, Belgium
3 shared publications Marcia Van Ginderen
Tibotec Virco Virology BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium
3 shared publications
Latest Publications
- 26 May 2026
- Published by Elsevier in Antiviral Research
- Vol. 251, 106440
Targeting dengue virus envelope protein: Insights from structural analysis and high-throughput screening
- 26 May 2026
- Published by Elsevier in Antiviral Research
- Vol. 251, 106440
Targeting dengue virus envelope protein: Insights from structural analysis and high-throughput screening
- Open Access
- 5 May 2026
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 22 (5) , e1014190
An orthoflavivirus inhibitor targeting multifunctional NS2A protein, a previously unidentified target
Orthoflaviviruses, such as dengue virus (DENV), Zika virus (ZIKV), West Nile virus (WNV), Japanese encephalitis virus (JEV), and yellow fever virus (YFV), constitute a significant public health concern with billions of people at risk of infection. Climate change and the expanding geographical distribution of mosquito vectors transmitting orthoflaviviruses have increased their potential to cause large-scale disease outbreaks. The frequency and severity of disease outbreaks highlight the urgent need for a broad-spectrum antiviral agent targeting orthoflaviviruses. In this work, we conducted a comprehensive morphological profiling of approximately 200,000 small molecules through a fluorescence-based high-content imaging platform, which led to the identification of a singular small molecule exhibiting broad-spectrum activity against orthoflaviviruses. Subsequent hit deconvolution against DENV serotype 2 (DENV-2) revealed NS2A protein as a novel therapeutic target. Mechanistically, JNJ-1953 inhibits viral RNA synthesis, as demonstrated by robust reductions in intracellular viral RNA and infectious virus production. Additional experiments show that JNJ-1953 further impacts viral RNA packaging and interferes with the interaction between NS2A and prM, rendering the molecule a multimodal inhibitor.
- 5 May 2026
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 22 (5) , e1014190
Open AccessAn orthoflavivirus inhibitor targeting multifunctional NS2A protein, a previously unidentified target
Orthoflaviviruses, such as dengue virus (DENV), Zika virus (ZIKV), West Nile virus (WNV), Japanese encephalitis virus (JEV), and yellow fever virus (YFV), constitute a significant public health concern with billions of people at risk of infection. Climate change and the expanding geographical distribution of mosquito vectors transmitting orthoflaviviruses have increased their potential to cause large-scale disease outbreaks. The frequency and severity of disease outbreaks highlight the urgent need for a broad-spectrum antiviral agent targeting orthoflaviviruses. In this work, we conducted a comprehensive morphological profiling of approximately 200,000 small molecules through a fluorescence-based high-content imaging platform, which led to the identification of a singular small molecule exhibiting broad-spectrum activity against orthoflaviviruses. Subsequent hit deconvolution against DENV serotype 2 (DENV-2) revealed NS2A protein as a novel therapeutic target. Mechanistically, JNJ-1953 inhibits viral RNA synthesis, as demonstrated by robust reductions in intracellular viral RNA and infectious virus production. Additional experiments show that JNJ-1953 further impacts viral RNA packaging and interferes with the interaction between NS2A and prM, rendering the molecule a multimodal inhibitor.
- Open Access
- 29 November 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (48) , eadr8338
The antiviral JNJ-A07 significantly reduces dengue virus transmission by Aedes aegypti mosquitoes when delivered via blood-feeding
Dengue virus (DENV) is the most widespread mosquito-borne virus worldwide, but no antiviral therapies are available yet. The pan-serotype DENV inhibitor JNJ-A07 has shown potent activity in a mouse model. It remains unknown whether an antiviral drug ingested by mosquitoes could inhibit virus replication and thus reduce transmission to other hosts. Here, we investigated the antiviral activity of JNJ-A07 when administered in the blood meal to Aedes aegypti mosquitoes. JNJ-A07 blocked DENV-2 transmission by the mosquitoes in both pre-exposure and post-exposure settings. In addition, JNJ-A07 remained in the mosquito bodies for 7 days after blood meal. Reductions of DENV systemic infection in the mosquitoes suggested a potential for decreased proportions of DENV outbreaks in a simulated environment when the mosquitoes ingested JNJ-A07 via the blood meal.
- 29 November 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (48) , eadr8338
Open AccessThe antiviral JNJ-A07 significantly reduces dengue virus transmission by Aedes aegypti mosquitoes when delivered via blood-feeding
Dengue virus (DENV) is the most widespread mosquito-borne virus worldwide, but no antiviral therapies are available yet. The pan-serotype DENV inhibitor JNJ-A07 has shown potent activity in a mouse model. It remains unknown whether an antiviral drug ingested by mosquitoes could inhibit virus replication and thus reduce transmission to other hosts. Here, we investigated the antiviral activity of JNJ-A07 when administered in the blood meal to Aedes aegypti mosquitoes. JNJ-A07 blocked DENV-2 transmission by the mosquitoes in both pre-exposure and post-exposure settings. In addition, JNJ-A07 remained in the mosquito bodies for 7 days after blood meal. Reductions of DENV systemic infection in the mosquitoes suggested a potential for decreased proportions of DENV outbreaks in a simulated environment when the mosquitoes ingested JNJ-A07 via the blood meal.
- Top Cited PapersOpen Access
- 15 March 2023
- Published by Springer Nature in Nature
- Vol. 615 (7953) , 678-686
Blocking NS3–NS4B interaction inhibits dengue virus in non-human primates
Dengue is a major health threat and the number of symptomatic infections caused by the four dengue serotypes is estimated to be 96 million1 with annually around 10,000 deaths2. However, no antiviral drugs are available for the treatment or prophylaxis of dengue. We recently described the interaction between non-structural proteins NS3 and NS4B as a promising target for the development of pan-serotype dengue virus (DENV) inhibitors3. Here we present JNJ-1802—a highly potent DENV inhibitor that blocks the NS3–NS4B interaction within the viral replication complex. JNJ-1802 exerts picomolar to low nanomolar in vitro antiviral activity, a high barrier to resistance and potent in vivo efficacy in mice against infection with any of the four DENV serotypes. Finally, we demonstrate that the small-molecule inhibitor JNJ-1802 is highly effective against viral infection with DENV-1 or DENV-2 in non-human primates. JNJ-1802 has successfully completed a phase I first-in-human clinical study in healthy volunteers and was found to be safe and well tolerated4. These findings support the further clinical development of JNJ-1802, a first-in-class antiviral agent against dengue, which is now progressing in clinical studies for the prevention and treatment of dengue.
- 15 March 2023
- Published by Springer Nature in Nature
- Vol. 615 (7953) , 678-686
Top Cited PapersOpen AccessBlocking NS3–NS4B interaction inhibits dengue virus in non-human primates
Dengue is a major health threat and the number of symptomatic infections caused by the four dengue serotypes is estimated to be 96 million1 with annually around 10,000 deaths2. However, no antiviral drugs are available for the treatment or prophylaxis of dengue. We recently described the interaction between non-structural proteins NS3 and NS4B as a promising target for the development of pan-serotype dengue virus (DENV) inhibitors3. Here we present JNJ-1802—a highly potent DENV inhibitor that blocks the NS3–NS4B interaction within the viral replication complex. JNJ-1802 exerts picomolar to low nanomolar in vitro antiviral activity, a high barrier to resistance and potent in vivo efficacy in mice against infection with any of the four DENV serotypes. Finally, we demonstrate that the small-molecule inhibitor JNJ-1802 is highly effective against viral infection with DENV-1 or DENV-2 in non-human primates. JNJ-1802 has successfully completed a phase I first-in-human clinical study in healthy volunteers and was found to be safe and well tolerated4. These findings support the further clinical development of JNJ-1802, a first-in-class antiviral agent against dengue, which is now progressing in clinical studies for the prevention and treatment of dengue.
- Open Access
- 1 August 2019
- Published by Elsevier in Antiviral Research
- Vol. 168, 109-113
Phylogenetically based establishment of a dengue virus panel, representing all available genotypes, as a tool in dengue drug discovery
- 1 August 2019
- Published by Elsevier in Antiviral Research
- Vol. 168, 109-113
Open AccessPhylogenetically based establishment of a dengue virus panel, representing all available genotypes, as a tool in dengue drug discovery
- 1 November 2017
- Published by Elsevier in Antiviral Research
- Vol. 147, 149-158
Characterization of a dengue NS4B inhibitor originating from an HCV small molecule library
- 1 November 2017
- Published by Elsevier in Antiviral Research
- Vol. 147, 149-158
Characterization of a dengue NS4B inhibitor originating from an HCV small molecule library
- 28 May 2013
- Published by Springer Nature
- Vol. 1030, 25-36
Biochemical Screening Assays to Identify HIV-1 Integrase Inhibitors
Human immunodeficiency virus type 1 (HIV-1) integrase is, in addition to reverse transcriptase and protease, an important enzymatic target for antiretroviral drug development. Integrase plays a critical role in the HIV-1 life cycle coordinating the integration of the reverse-transcribed viral DNA into the host genome. This integration step is the net result of two consecutive integrase-related processes. First, integrase removes a dinucleotide from the 3′ viral DNA ends in a process called 3′-processing. Next, in a process called strand transfer, the viral DNA is integrated into the host genomic DNA. Early on, biochemical assays have played a critical role in understanding the function of HIV-1 integrase and the discovery of small-molecule inhibitors. In this chapter we describe two biochemical assays to identify inhibitors of the 3′-processing and strand transfer process of HIV-1 integrase.
- 28 May 2013
- Published by Springer Nature
- Vol. 1030, 25-36
Biochemical Screening Assays to Identify HIV-1 Integrase Inhibitors
Human immunodeficiency virus type 1 (HIV-1) integrase is, in addition to reverse transcriptase and protease, an important enzymatic target for antiretroviral drug development. Integrase plays a critical role in the HIV-1 life cycle coordinating the integration of the reverse-transcribed viral DNA into the host genome. This integration step is the net result of two consecutive integrase-related processes. First, integrase removes a dinucleotide from the 3′ viral DNA ends in a process called 3′-processing. Next, in a process called strand transfer, the viral DNA is integrated into the host genomic DNA. Early on, biochemical assays have played a critical role in understanding the function of HIV-1 integrase and the discovery of small-molecule inhibitors. In this chapter we describe two biochemical assays to identify inhibitors of the 3′-processing and strand transfer process of HIV-1 integrase.
- 31 August 2011
- Published by Elsevier in Antiviral Research
- Vol. 91 (2) , 167-176
Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor
- 31 August 2011
- Published by Elsevier in Antiviral Research
- Vol. 91 (2) , 167-176
Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor
- 1 November 2009
- Published by Elsevier in Antiviral Research
- Vol. 84 (2) , 142-149
Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes
- 1 November 2009
- Published by Elsevier in Antiviral Research
- Vol. 84 (2) , 142-149
Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes